CN1772753A - 一种防治老年痴呆的中药活性成分化合物及其制备和用途 - Google Patents
一种防治老年痴呆的中药活性成分化合物及其制备和用途 Download PDFInfo
- Publication number
- CN1772753A CN1772753A CN 200510095024 CN200510095024A CN1772753A CN 1772753 A CN1772753 A CN 1772753A CN 200510095024 CN200510095024 CN 200510095024 CN 200510095024 A CN200510095024 A CN 200510095024A CN 1772753 A CN1772753 A CN 1772753A
- Authority
- CN
- China
- Prior art keywords
- group
- preparation
- compound
- day
- senile dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 19
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000004480 active ingredient Substances 0.000 title claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 15
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- 238000010992 reflux Methods 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 230000006837 decompression Effects 0.000 claims description 8
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000004809 thin layer chromatography Methods 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000011218 segmentation Effects 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 235000008216 herbs Nutrition 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001471 micro-filtration Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 abstract description 5
- 239000000969 carrier Substances 0.000 abstract 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 229960004526 piracetam Drugs 0.000 description 25
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 230000015654 memory Effects 0.000 description 16
- 230000003203 everyday effect Effects 0.000 description 14
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229960004756 ethanol Drugs 0.000 description 10
- 238000012549 training Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 6
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 6
- 229960002646 scopolamine Drugs 0.000 description 6
- 235000010288 sodium nitrite Nutrition 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 150000002213 flavones Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010021703 Indifference Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000004880 oxines Chemical class 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009189 diving Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- FWQHRZXEQNUCSY-UHFFFAOYSA-N tert-butyl N-[2-(ethoxycarbonylamino)-5-[(4-fluorophenyl)methyl-prop-2-ynylamino]phenyl]carbamate Chemical compound CCOC(=O)NC1=C(C=C(C=C1)N(CC#C)CC2=CC=C(C=C2)F)NC(=O)OC(C)(C)C FWQHRZXEQNUCSY-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 241000913796 Fordia cauliflora Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- -1 flavonoid compound Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FOGVNFMUZXDMTR-UHFFFAOYSA-N [Mg].Cl Chemical compound [Mg].Cl FOGVNFMUZXDMTR-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
position | δH | δC | position | δH | δC |
23456784a8a2CH3 | 6.80(1H,s,H-3)7.91(1H,d,J=8.8Hz,)7.10(1H,d,J=8.8Hz)1.52 | 157.72107.8176.77125.91115.22152.53110.29121.69147.1927.72 | 1′2′3′4′5′6′2″3″4″ | 8.13(1H,H-2′)7.59(3H,m,H-3′,4′,5′)8.13(1H,H-6′)6.92(1H,d,J=10Hz)5.98(1H,d,J=10Hz) | 131.83126.58129.52131.36129.52126.5878.08118.25131.39 |
组别 | 动物数 | 潜伏期(s) | 错误次数 | |
训练 | 测试 | |||
controlpiracetamhighmiddle | 10101010 | 66.36±63.12174.42±74.31***100.68±59.35**161.87±56.93*** | 4.88±1.894.18±2.563.25±1.165.25±2.60 | 9.25±4.394.87±1.81***4.62±1.77***5.12±1.55*** |
low | 10 | 154.44±69.55** | 6.89±2.57 | 6.37±2.61** |
组别 | 第一天 | 第二天 | 第三天 | 第四天 | 第五天 |
modelcontrolpirahighmiddlelow | 110.81±25.88104.18±36.49106.9±31.35113.59±25.22101.25±37.97115.0±19.45 | 110.59±28.83▲▲▲85.89±44.24***△△100.23±38.75111.25±28.23△94.0±39.94*113.03±25.47▲▲▲ | 107.92±29.66▲▲▲※※75.45±48.15***△△76.54±47.07**△△110.00±27.50▲▲▲※※※81.63±45.45**△△103.73±34.63▲▲※※ | 104.64±30.43▲▲▲※※73.46±48.85***△△59.63±44.21**△△99.5±36.49▲▲▲※※※75.56±50.43***△△99.25±39.92▲▲△※※ | 99.17±37.52▲▲▲△※※51.70±48.40***△△50.52±48.52**△△99.23±36.57▲▲▲△※※※71.79±50.36**▲△△※82.75±49.07▲▲△△※※ |
组别 | 第一天 | 第二天 | 第三天 | 第四天 | 第五天 |
modelcontrolpiracetamHRRMRRLRR | 107.67±28.59101±40.02101.25±35.65102.65±33.8096.75±43.02100.05±33.24 | 103.83±31.42▲▲※77.5±46.34**△86.70±42.68*△87.59±42.13*△76.48±50.91△**99.41±39.33▲ | 99.31±33.93▲▲69.23±49.50***△△89.16±44.74*△80.33±44.68*△75.1±50.16△*78.80±49.56△* | 89.02±42.39▲△△64.77±48.29***△△※84.98±46.37*△▲62.68±48.99△△**※66.18±48.68△*71.57±50.46△ | 85.08±41.75▲▲▲△△36.93±40.42***△△※※68.95±47.02*△△▲▲▲60.85±51.25△△*44.53±42.43△△***※63.57±51.56△△*▲▲ |
组别 | 第五天 | 第六天 | 灌胃20%乙醇后 | 潜伏期延长 |
百分率 | ||||
ModelControlPiracetamhighmiddlelow | 47.78±49.3141.90±44.4247.78±38.6163.31±50.43▲▲21.48±22.14▲▲**※※※45.03±43.66 | 44.68±48.8737.75±41.3855.8±47.91▲42.56±43.8418.38±17.42▲▲**※※※42.88±42.34 | 48.53±45.08※※32.72±38.9984.97±48.82**▲▲▲△63.59±50.29▲▲△△10.13±10.19***▲▲※※※△67.28±52.55▲▲△ | 8.61-13.3252.2849.41-44.8957.00 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100950240A CN100545163C (zh) | 2005-10-26 | 2005-10-26 | 一种防治老年痴呆的中药活性成分化合物及其制备和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100950240A CN100545163C (zh) | 2005-10-26 | 2005-10-26 | 一种防治老年痴呆的中药活性成分化合物及其制备和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1772753A true CN1772753A (zh) | 2006-05-17 |
CN100545163C CN100545163C (zh) | 2009-09-30 |
Family
ID=36759912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100950240A Expired - Fee Related CN100545163C (zh) | 2005-10-26 | 2005-10-26 | 一种防治老年痴呆的中药活性成分化合物及其制备和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100545163C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102115477A (zh) * | 2009-12-31 | 2011-07-06 | 广西壮族自治区花红药业股份有限公司 | 2",2"-二甲基-吡喃-[5",6":7,8]黄酮的制备方法 |
US9527860B2 (en) | 2011-06-17 | 2016-12-27 | Ludwig Aigner | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders |
-
2005
- 2005-10-26 CN CNB2005100950240A patent/CN100545163C/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102115477A (zh) * | 2009-12-31 | 2011-07-06 | 广西壮族自治区花红药业股份有限公司 | 2",2"-二甲基-吡喃-[5",6":7,8]黄酮的制备方法 |
CN102115477B (zh) * | 2009-12-31 | 2013-12-11 | 广西壮族自治区花红药业股份有限公司 | 2”,2”-二甲基-吡喃-[5”,6”:7,8]黄酮的制备方法 |
US9527860B2 (en) | 2011-06-17 | 2016-12-27 | Ludwig Aigner | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders |
US9956199B2 (en) | 2011-06-17 | 2018-05-01 | Ludwig Aigner | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders |
Also Published As
Publication number | Publication date |
---|---|
CN100545163C (zh) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1853682A (zh) | 用于改善睡眠持续时间和质量的基于植物的食品强化剂 | |
CN1301666C (zh) | 一种能增强免疫力的保健食品及其制备方法 | |
CN1457808A (zh) | 一种铁皮石斛复方制剂及制备和应用 | |
CN1733662A (zh) | 蒲葵的抗肿瘤提取物及其制备方法及应用 | |
CN1907316A (zh) | 一种预防和治疗骨科疾病的药物组合物 | |
CN109718273A (zh) | 紫苏叶提取物在预防或治疗骨性关节炎中的应用 | |
CN1742775A (zh) | 一种预防和治疗骨科疾病的药物组合物 | |
CN1283281C (zh) | 一种含酸枣仁、灵芝、人参叶药物组合物及其制备和应用 | |
CN1772753A (zh) | 一种防治老年痴呆的中药活性成分化合物及其制备和用途 | |
CN1723936A (zh) | 一种抗抑郁症的中药及其制备方法 | |
CN109806304A (zh) | 三叶悬钩子植物提取物及其药物组合物的制备方法与抗旋毛虫用途 | |
CN1506090A (zh) | 藏边大黄提取物和以该提取物为活性成分的药物组合物 | |
CN1548053A (zh) | 黄芩甙作为治疗焦虑症的药物的新用途 | |
CN107519327A (zh) | 一种桑黄中药组合物及其提取方法和在制备抗肿瘤药物中的应用 | |
CN1246326C (zh) | 化合物菠萝黄酮苷及用途 | |
CN104546987A (zh) | 绞股蓝总皂苷在防治高尿酸血症中的应用 | |
CN103565819A (zh) | 一种抑制肿瘤干细胞的组合物 | |
JP6467345B2 (ja) | 脂肪蓄積抑制剤、脂肪肝の予防剤又は治療剤及び脂肪酸合成酵素抑制剤 | |
CN105497167A (zh) | 猫爪草在制备治疗和/或预防溃疡性结肠炎药物方面的新用途 | |
CN1137698C (zh) | 含花生叶提取物的制剂及制备方法 | |
CN1290566C (zh) | 治疗抑郁症的药物制剂及其制备方法 | |
CN1272047C (zh) | 一种补益肝肾治疗肠燥便秘的药物 | |
CN1771839A (zh) | 复方营养保健品 | |
CN1282470C (zh) | 一种抗抑郁中药及其制备方法 | |
CN104130232B (zh) | 一种egcg的提纯方法及获得的egcg和药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: CHANGZHOU TAIKANG PHARMACEUTICAL Co.,Ltd. Assignor: Nanjing Tech University Contract record no.: 2011320000729 Denomination of invention: Chinese medicine active compound component for treating senile dementia and its prepn and use Granted publication date: 20090930 License type: Exclusive License Open date: 20060517 Record date: 20110520 |
|
ASS | Succession or assignment of patent right |
Owner name: CHANGZHOU TAIKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANJING UNIVERSITY OF TECHNOLOGY Effective date: 20111129 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 210038 CHANGZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20111129 Address after: 210038 fruit Road, Wujin Economic Development Zone, Jiangsu, Changzhou Patentee after: CHANGZHOU TAIKANG PHARMACEUTICAL Co.,Ltd. Address before: 210009 Zhongshan North Road, Jiangsu, No. 200, Patentee before: Nanjing Tech University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090930 Termination date: 20161026 |
|
CF01 | Termination of patent right due to non-payment of annual fee |